Back to Journals » Vascular Health and Risk Management » Volume 4 » Issue 1

Gadofosveset-enhanced magnetic resonance angiography

Authors Goyen M

Published 8 February 2008 Volume 2008:4(1) Pages 1—9

DOI https://doi.org/10.2147/VHRM.S1968


Mathias Goyen

University Medical Center Hamburg- Eppendorf, Hamburg, Germany

Abstract: Gadofosveset (Vasovist®, Bayer Schering Pharma AG, Berlin/Germany) is the first intravascular contrast agent approved for use with magnetic resonance angiography in the European Union, Switzerland, Turkey, Canada, and Australia. Gadofosveset reversibly binds to albumin providing extended intravascular enhancement compared with existing extracellular magnetic resonance contrast agents. Prior to approval, gadofosveset underwent extensive testing to evaluate the safety and efficacy of the drug; the clinical trials show that gadofosveset-enhanced magnetic resonance angiography (MRA) is safe and well tolerated in patients with vascular disease and effective for the detection of vascular stenosis and aneurysms gadofosveset has the potential to open new horizons in diagnostic MRA by increasing the spatial resolution and the robustness of MRA examinations and facilitating the examination of multiple vascular beds.

Keywords: gadofosveset, Vasovist®, magnetic resonance imaging, magnetic resonance contrast agent, magnetic resonance angiography (MRA)

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]